



MEN

FIRST CANCER SITE  
**LYMPHOID  
LEUKAEMIAS**

LYMPHOID LEUKAEMIAS  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LEUCEMIE LINFODI  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	10570		11524		11524		10570		8739		3994		1313		10570	11524
Person-years ▶	49446		51273		1827		7992		24299		12409		4745		49446	51273
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LYMPHOID LEUKAEMIAS	927	1.05	1058	1.16	131	4.07	146	1.05	453	1.03	240	1.06	88	1.15	0.91	2.81
HEAD AND NECK	35	1.00	40	1.10	5	3.72	3	0.51	18	1.01	8	0.94	6	2.25	0.00	0.07
ORAL CAVITY	8	0.97	8	0.94	0	0.00	0	0.00	2	0.48	4	1.97	2	3.06	0.00	-0.01
PHARYNX	6	0.82	7	0.92	1	3.61	0	0.00	3	0.80	2	1.11	1	1.77	-0.03	-0.01
LARYNX	21	1.08	25	1.24	4	5.29	3	0.91	13	1.31	2	0.42	3	2.06	0.03	0.09
OESOPHAGUS	4	0.43	4	0.42	0	0.00	0	0.00	3	0.64	0	0.00	1	1.34	-0.11	-0.11
STOMACH	51	0.94	56	0.99	5	2.33	8	0.88	23	0.83	17	1.27	3	0.68	-0.07	-0.01
COLON RECTUM	140	1.15	147	1.16	7	1.59	15	0.79	73	1.21	34	1.08	18	1.66	0.37	0.41
COLON	101	1.20	104	1.20	3	1.00	10	0.77	54	1.30	23	1.05	14	1.84	0.35	0.33
RECTUM	39	1.03	43	1.09	4	2.85	5	0.83	19	1.00	11	1.14	4	1.24	0.02	0.07
LIVER	24	0.67	27	0.73	3	2.30	5	0.88	13	0.73	4	0.44	2	0.67	-0.24	-0.19
GALLBLADDER	3	0.31	3	0.30	0	0.00	0	0.00	3	0.61	0	0.00	0	0.00	-0.14	-0.14
PANCREAS	17	0.70	18	0.72	1	1.14	3	0.79	7	0.58	5	0.80	2	0.94	-0.15	-0.14
LUNG	204	1.32	260	1.62	56	9.68	29	1.16	103	1.32	60	1.54	12	0.95	1.00	1.94
SKIN MELANOMA	31	2.58	34	2.74	3	7.41	4	2.24	15	2.57	9	2.82	3	2.55	0.38	0.42
MESOTHELIOMA	7	1.52	9	1.89	2	12.75	0	0.00	6	2.64	1	0.82	0	0.00	0.05	0.08
KAPOSI SARCOMA	11	5.68	15	7.46	4	54.12	2	6.31	3	3.08	4	8.28	2	12.21	0.18	0.25
SOFT TISSUE	6	1.94	6	1.87	0	0.00	1	2.04	3	1.96	1	1.26	1	3.57	0.06	0.05
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	3	1.59	4	2.04	1	14.56	0	0.00	1	1.06	2	4.11	0	0.00	0.02	0.04
PROSTATE	163	0.93	167	0.92	4	0.66	24	0.91	78	0.91	45	0.96	16	1.00	-0.24	-0.28
TESTIS	1	0.81	2	1.57	1	22.96	1	5.27	0	0.00	0	0.00	0	0.00	0.00	0.01
KIDNEY AND RENAL PELVIS	39	1.46	45	1.62	6	6.33	17	4.10	14	1.05	5	0.72	3	1.27	0.25	0.34
BLADDER AND URINARY TRACT	102	1.03	123	1.19	21	5.73	21	1.33	49	0.99	24	0.95	8	0.94	0.05	0.39
URINARY BLADDER	98	1.03	118	1.20	20	5.70	19	1.26	49	1.03	22	0.91	8	0.99	0.06	0.38
URINARY TRACT	4	0.91	5	1.10	1	6.23	2	2.90	0	0.00	2	1.78	0	0.00	-0.01	0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	16	1.61	17	1.65	1	2.73	3	1.88	11	2.20	1	0.40	1	1.18	0.12	0.13
THYROID	6	1.57	6	1.52	0	0.00	1	1.71	1	0.54	1	1.01	3	8.16	0.04	0.04
HODGKIN LYMPHOMA	6	3.17	7	3.57	1	14.47	0	0.00	2	2.21	3	6.29	1	4.78	0.08	0.10
NON-HODGKIN LYMPHOMA	14	0.56	14	0.54	0	0.00	2	0.51	5	0.40	6	0.94	1	0.45	-0.22	-0.23
MYELOMA	1	0.08	1	0.08	0	0.00	0	0.00	1	0.17	0	0.00	0	0.00	-0.22	-0.22
LEUKAEMIAS	6	0.29	6	0.28	0	0.00	1	0.29	3	0.28	2	0.38	0	0.00	-0.30	-0.31
LYMPHOID LEUKAEMIAS	1	0.10	1	0.10	0	0.00	1	0.60	0	0.00	0	0.00	0	0.00	-0.18	-0.19
MYELOID LEUKAEMIAS	5	0.54	5	0.52	0	0.00	0	0.00	3	0.65	2	0.84	0	0.00	-0.09	-0.09
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	38	0.81	48	0.98	10	5.71	7	0.93	18	0.77	8	0.66	5	1.20	-0.19	-0.02

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**LYMPHOID  
LEUKAEMIAS**

**LYMPHOID LEUKAEMIAS  
POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LEUCEMIE LINFODI  
POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	7694	8497		8497		7694		6350		3033		1143		7694	8497
Person-years ▶	38208	39546		1338		5796		17895		9889		4628		38208	39546	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LYMPHOID LEUKAEMIAS	411	1.04	473	1.15	62	4.40	72	1.20	166	0.88	133	1.28	40	0.95	0.40	1.60
HEAD AND NECK	5	1.02	5	0.98	0	0.00	1	1.34	1	0.42	2	1.54	1	1.91	0.00	0.00
ORAL CAVITY	3	1.08	3	1.05	0	0.00	1	2.44	0	0.00	1	1.36	1	3.26	0.01	0.00
PHARYNX	1	1.00	1	0.97	0	0.00	0	0.00	0	0.00	1	3.86	0	0.00	0.00	0.00
LARYNX	1	0.87	1	0.84	0	0.00	0	0.00	1	1.79	0	0.00	0	0.00	0.00	0.00
OESOPHAGUS	1	0.48	2	0.92	1	13.27	0	0.00	1	1.00	0	0.00	0	0.00	-0.03	0.00
STOMACH	34	1.31	34	1.26	0	0.00	6	1.46	14	1.11	11	1.66	3	1.15	0.21	0.18
COLON RECTUM	78	1.21	82	1.23	4	1.74	11	1.13	36	1.17	23	1.35	8	1.16	0.36	0.39
COLON	58	1.25	60	1.24	2	1.22	9	1.29	27	1.22	14	1.13	8	1.59	0.30	0.30
RECTUM	20	1.12	22	1.19	2	3.08	2	0.73	9	1.04	9	1.93	0	0.00	0.06	0.09
LIVER	10	0.86	10	0.83	0	0.00	0	0.00	5	0.90	3	0.98	2	1.64	-0.04	-0.05
GALLBLADDER	8	0.85	9	0.92	1	2.86	1	0.68	3	0.66	4	1.64	0	0.00	-0.04	-0.02
PANCREAS	15	0.86	15	0.83	0	0.00	3	1.17	8	0.97	2	0.43	2	1.01	-0.07	-0.08
LUNG	44	1.74	55	2.10	11	12.84	8	2.17	18	1.50	14	2.06	4	1.41	0.49	0.73
SKIN MELANOMA	10	1.49	13	1.88	3	13.18	1	1.02	3	0.95	6	3.39	0	0.00	0.09	0.15
MESOTHELIOMA	1	0.96	2	1.86	1	29.38	0	0.00	1	2.04	0	0.00	0	0.00	0.00	0.02
KAPOSI SARCOMA	1	1.63	1	1.58	0	0.00	0	0.00	1	3.41	0	0.00	0	0.00	0.01	0.01
SOFT TISSUE	2	1.21	3	1.76	1	17.33	1	4.04	0	0.00	0	0.00	1	5.40	0.01	0.03
BONE	1	2.02	1	1.95	0	0.00	0	0.00	0	0.00	0	0.00	1	18.27	0.01	0.01
BREAST	96	1.04	119	1.24	23	7.01	14	0.99	42	0.94	32	1.33	8	0.84	0.10	0.59
CERVIX UTERI	3	0.63	3	0.61	0	0.00	1	1.27	1	0.43	1	0.86	0	0.00	-0.05	-0.05
CORPUS UTERI	6	0.36	7	0.41	1	1.66	1	0.38	2	0.25	3	0.70	0	0.00	-0.28	-0.26
OVARY	10	0.84	13	1.05	3	6.91	4	2.15	3	0.52	2	0.65	1	0.82	-0.05	0.02
KIDNEY AND RENAL PELVIS	12	1.27	13	1.33	1	3.10	6	4.32	2	0.44	3	1.18	1	0.96	0.07	0.08
BLADDER AND URINARY TRACT	17	1.06	23	1.39	6	10.66	5	2.09	2	0.26	9	2.13	1	0.58	0.03	0.16
URINARY BLADDER	17	1.15	23	1.50	6	11.49	5	2.26	2	0.28	9	2.30	1	0.63	0.06	0.19
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	7	1.22	8	1.35	1	4.97	2	2.30	2	0.73	2	1.34	1	1.63	0.03	0.05
THYROID	5	0.86	5	0.83	0	0.00	2	2.30	2	0.73	0	0.00	1	1.41	-0.02	-0.03
HODGKIN LYMPHOMA	3	2.83	5	4.57	2	57.11	0	0.00	1	2.16	2	7.21	0	0.00	0.05	0.10
NON-HODGKIN LYMPHOMA	13	0.87	13	0.84	0	0.00	0	0.00	5	0.70	5	1.27	3	1.89	-0.05	-0.06
MYELOMA	1	0.14	1	0.13	0	0.00	0	0.00	1	0.29	0	0.00	0	0.00	-0.16	-0.16
LEUKAEMIAS	3	0.28	4	0.36	1	2.56	1	0.61	1	0.19	1	0.36	0	0.00	-0.20	-0.18
LYMPHOID LEUKAEMIAS	0	0.00	1	0.20	1	5.48	0	0.00	0	0.00	0	0.00	0	0.00	-0.13	-0.10
MYELOID LEUKAEMIAS	3	0.61	3	0.59	0	0.00	1	1.36	1	0.43	1	0.77	0	0.00	-0.05	-0.05
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	25	0.77	28	0.84	3	2.60	4	0.83	11	0.72	8	0.94	2	0.56	-0.19	-0.14

■ Decrease/Difetto    ○ Observed cases    ■ SIR Standardized Incidence Ratio    ■ EAR Excess Absolute Risk  
■ Increase/Eccesso    ○ Casi osservati    ■ Rapporto standardizzato di incidenza    ■ Eccesso assoluto di rischio